DexCom Inc. stock falls 3.40% and underperforms competitors in grim market session
Updated
Updated · MarketWatch · Apr 28
DexCom Inc. stock falls 3.40% and underperforms competitors in grim market session
10 articles · Updated · MarketWatch · Apr 28
DexCom shares closed at $59.32 on Tuesday, marking their fourth consecutive day of losses and trading 34.07% below the 52-week high.
Trading volume reached 5.6 million, surpassing the 50-day average of 4.2 million, while Abbott Laboratories rose 1.14% and Insulet Corp. dropped 2.89%.
The S&P 500 fell 0.49% and the Dow Jones slipped 0.05%, reflecting broader market weakness impacting DexCom’s performance relative to peers.
How will DexCom's upcoming Investor Day address the growing competitive pressure from its chief rival, Abbott?
Is DexCom's stock undervalued, or is the market correctly pricing in the threat from Abbott's cheaper CGM?
With its stock falling, can DexCom's new Stelo device win the consumer health market before Big Tech enters?
Will expanded Medicare coverage create a windfall for DexCom, or will reimbursement hurdles limit its growth?
How will DexCom's next-generation G8 sensor and AI features maintain its technological edge in the market?
Could the rise of GLP-1 weight loss drugs unexpectedly become a major growth driver for CGM sales?